Rui-Ru Ji

Title: Innovations and Contributions of Inventor Rui-Ru Ji

Introduction

Rui-Ru Ji is a notable inventor based in Belmont, MA (US). He has made significant contributions to the field of cancer treatment and genetic research. With a total of 2 patents, his work focuses on innovative methods for improving patient outcomes in oncology.

Latest Patents

One of Rui-Ru Ji's latest patents is titled "Biomarker signature for predicting tumor response to anti-CD200 therapy." This patent outlines methods for treating cancer patients who exhibit positive expression of the CD200 receptor (CD200R1) and specific biomarkers. The methods involve administering a CD200 inhibitor and monitoring the patient's responsiveness to the treatment by analyzing expression levels of various biomarkers.

Another significant patent is "N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods." This patent addresses potentially pathogenic mutations in the nucleotide sequence of the human NAGLU gene. It highlights the association of certain NAGLU gene variants with reduced N-acetyl-alpha-D-glucosaminidase (NAGLU) activity, which is crucial for understanding genetic disorders.

Career Highlights

Rui-Ru Ji is currently employed at Alexion Pharmaceuticals, Inc., where he continues to advance his research and innovations in the pharmaceutical industry. His work is instrumental in developing therapies that target specific cancer pathways and genetic conditions.

Collaborations

Rui-Ru Ji collaborates with esteemed colleagues, including Mark L Hamilton and Sharon Barr. These partnerships enhance the research efforts and contribute to the development of groundbreaking therapies.

Conclusion

Rui-Ru Ji's contributions to the fields of cancer treatment and genetic research are noteworthy. His innovative patents and collaborations reflect his commitment to improving patient care and advancing scientific knowledge.